Search

Your search keyword '"Pang, Yizhen"' showing total 246 results
Start Over Author "Pang, Yizhen" Search Limiters Peer Reviewed
246 results on '"Pang, Yizhen"'

3. Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study

Author

Guo, Wei, Wen, Xuejun, Chen, Yuhang, Zhao, Tianzhi, Liu, Jia, Tao, Yucen, Fu, Hao, Wang, Hongjian, Xu, Weizhi, Pang, Yizhen, Zhao, Liang, Huang, Jingxiong, Xu, Pengfei, Guo, Zhide, Miao, Weibing, Zhang, Jingjing, Chen, Xiaoyuan, and Chen, Haojun

Published
2024
Full Text
View/download PDF

23. Enhanced Detection of Early Pulmonary Fibrosis Disease Using 68Ga-FAPI-LM3 PET

Author

Chen, Jianhao, Luo, Doudou, Dai, Yaqing, Zhou, Yangfan, Pang, Yizhen, Wu, Hua, Sun, Long, Su, Guoqiang, Lin, Qin, Zhao, Liang, and Chen, Haojun

Abstract

Early detection of pulmonary fibrosis is a critical yet insufficiently met clinical necessity. This study evaluated the effectiveness of FAPI-LM3, a 68Ga-radiolabeled heterobivalent molecular probe that targets fibroblast activating protein (FAP) and somatostatin receptor 2 (SSTR2), in the early detection of pulmonary fibrosis, leveraging its potential for early disease identification. A bleomycin-induced early pulmonary fibrosis model was established in C57BL/6 mice for 7 days. FAP and SSTR2 expression levels were quantitatively assessed in human idiopathic pulmonary fibrosis lung tissue samples and bleomycin-treated mouse lung tissues by using western blotting, real-time quantitative PCR (RT-qPCR), and immunofluorescence techniques. The diagnostic performance of FAPI-LM3 was investigated by synthesizing monomeric radiotracers 68Ga-FAPI-46 and 68Ga-DOTA-LM3 alongside the heterobivalent probe 68Ga-FAPI-LM3. These imaging radiopharmaceuticals were used in small-animal PET to compare their uptake in fibrotic and normal lung tissues. Results indicated significant upregulation of FAP and SSTR2 at both RNA and protein levels in fibrotic lung tissues compared with that in normal controls. PET imaging demonstrated significantly enhanced uptake of the 68Ga-FAPI-LM3 probe in fibrotic lung tissues, with superior visual effects compared to monomeric tracers. At 60 min postinjection, early stage fibrotic tissues (day 7) demonstrated low-to-medium uptake of monomeric probes, including 68Ga-DOTA-LM3 (0.45 ± 0.04% ID/g) and 68Ga-FAPI-46 (0.78 ± 0.09% ID/g), whereas the uptake of the heterobivalent probe 68Ga-FAPI-LM3 (1.90 ± 0.10% ID/g) was significantly higher in fibrotic lesions than in normal lung tissue. Blockade experiments confirmed the specificity of 68Ga-FAPI-LM3 uptake, which was attributed to synergistic targeting of FAP and SSTR2. This study demonstrates the potential of 68Ga-FAPI-LM3 for early pulmonary fibrosis detection via molecular imaging, offering significant benefits over monomeric tracers 68Ga-FAPI-46 and 68Ga-DOTA-LM3. This strategy offers new possibilities for noninvasive and precise early detection of pulmonary fibrosis.

Published
2024
Full Text
View/download PDF

31. Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study

Author

Fu, Hao, primary, Huang, Jingxiong, additional, Zhao, Tianzhi, additional, Wang, Hongjian, additional, Chen, Yuhang, additional, Xu, Weizhi, additional, Pang, Yizhen, additional, Guo, Wei, additional, Sun, Long, additional, Wu, Hua, additional, Xu, Pengfei, additional, Su, Bishan, additional, Zhang, Jingjing, additional, Chen, Xiaoyuan, additional, and Chen, Haojun, additional

Published
2023
Full Text
View/download PDF

47. Gallium-68-Labelled Fibroblast Activation Protein Inhibitor PET/CT in the clinical diagnosis and management of breast cancer: Comparison with [18F]FDG PET/CT

Author

Guo, Wei, primary, Xu, Weizhi, additional, Fan, Chunlei, additional, Fu, Hao, additional, Meng, Tinghua, additional, Pang, Yizhen, additional, Zhao, Liang, additional, Fu, Li, additional, Sun, Long, additional, Mi, Yanjun, additional, Huang, Jingxiong, additional, and Chen, Haojun, additional

Published
2022
Full Text
View/download PDF

48. SSTR antagonist [68Ga]Ga-DOTA-LM3 differentiates intrapancreatic accessory spleen from neuroendocrine tumor in a patient presenting indeterminate MRI and SSTR agonist [68Ga]Ga-DOTATATE.

Author

Xu, Weizhi, Cai, Jiayu, Meng, Tinghua, Pang, YiZhen, and Chen, Haojun

Subjects
NEUROENDOCRINE tumors, SPLEEN, MAGNETIC resonance imaging, COMPUTED tomography
Abstract

A 46-year-old woman presented with upper abdominal pain and was initially suspected to have a pancreatic neuroendocrine tumor (NET) based on MRI signs. However, a SSTR2-targeted PET/CT scan using [68Ga]Ga-DOTATATE showed intense radiotracer uptake in the pancreatic nodule, similar to the adjacent spleen. To further differentiate between the two, a [68Ga]Ga-DOTA-LM3 PET/CT scan was performed, which showed no increased uptake in the pancreatic nodule, indicating a lower likelihood of neoplasia. A laparoscopic distal pancreatectomy confirmed the presence of an intrapancreatic accessory spleen (IPAS). This case highlights the challenges in differentiating pancreatic NETs from IPAS and suggests that [68Ga]Ga-DOTA-LM3 PET/CT may be helpful in making this distinction. [Extracted from the article]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results